Chemotherapy plus bevacizumab or anti-EGFR antibody is recommended for the second-line therapy of RAS wild-type mCRC regardless of sidedness. However, these recommendations are based on the limited data from the retrospective analyses of prior trials, warranting further prospective randomized trials....
Currently, the identification of biological markers predictive of therapy response and the accurate molecular screening of cancer patients aimed to gain most clinical benefits become decisive and mandatory. 展开 关键词: EGFR EGFR-TKIs Src kinase family c-Src inhibitors drug resistance ...
Gefitinib is a medication used to treat certain cancers, specifically non-small cell lung cancer (NSCLC). By targeting the epidermal growth factor receptor (EGFR) and inhibiting its tyrosine kinase activity, gefitinib helps restore balance in cell proliferation. It is particularly effective in NSCLC ...
EGFR+ is epidermal growth factor receptor mutation-positive; NSCLC is non-small cell lung cancer. IMPORTANT SAFETY INFORMATION TAGRISSO is an FDA-approved oral targeted therapy used when your NSCLC with certain abnormal EGFR gene(s)* has spread to nearby tissues (locally advanced), that is unable...
Engineered cancer-specific TCR-T cells is one of the current immunotherapy strategies designed with the aim of improving antitumor T-cell responses in patients. It is a directed therapy using TCR of T cells that specifically target/recognize cells expressing particular antigen such as CTAs. Careful...
Curtin says this targeted therapy represents “a significant and important innovation in this field of EGFR-mutated lung cancer.” Johnson & Johnsonsubmitted the findings of new research to health regulatory authorities in hopes of making treatment options available to broader patient populations with EG...
Acute ischemic stroke: overview of major experimental rodent models, pathophysiology, and therapy of focal cerebral ischemia. Pharmacol Biochem Behav 2007; 87: 179–97. 7 McCabe C, Gallagher L, Gsell W, Graham D, Dominiczak AF, Macrae IM. Differences in the evolution of the ischemic penumbra...
Colorectal cancer and antiangiogenic therapy: What can be expected in clinical practice? Angiogenesis is a strongly regulated process, which is dependent upon a complex interplay between inhibitory and stimulatory angiogenic factors. It is esse... A Mancuso,CN Sternberg - 《Critical Reviews in Oncolog...
Beyond trastuzumab therapy, a second wave of monoclonal antibodies and tyrosine kinase inhibitors has emerged. These drugs have variable properties including: 1) dual inhibition against EGFR and HER-2, such as lapatinib, HKI-272 and pertuzumab; 2) antiangiogenesis such as bevacizumab and pazopanib;...
Thus, the choice of first-line targeted therapy based on the detection of these biomarkers with cytological and liquid biological samples is and could be a complementary approach to tissue biopsies [42,44]. 2.1. EGFR, ALK, ROS1, BRAF, and NTRK: What Is New for the “Big Five” When ...